Gemtuzumab ozogamicin for acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) is a significant hematologic malignancy.
• CD33 expression is common in AML, making it a target for therapy.
• Previous approvals and withdrawals highlight the complex history of gemtuzumab ozogamicin.

Purpose of the Study:

• To summarize the FDA approval of gemtuzumab ozogamicin (GO).
• To detail the indications for GO in acute myeloid leukemia (AML).
• To contextualize GO as the first approved antibody-drug conjugate.

Main Methods:

• Review of FDA approval documentation.
• Analysis of clinical trial data supporting efficacy and safety.
• Historical review of gemtuzumab ozogamicin's development and regulatory status.

Main Results:

• Gemtuzumab ozogamicin (GO) received FDA approval on September 1, 2017.
• Approved for adults with newly diagnosed CD33+ AML.
• Approved for relapsed or refractory CD33+ AML patients aged ≥2 years.

Conclusions:

• The FDA approval marks a new phase for gemtuzumab ozogamicin.
• GO represents a significant advancement as the first antibody-drug conjugate approved by the FDA.
• This approval provides a crucial therapeutic option for specific AML patient populations.